Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.29
21.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Tianjin Ringpu Bio-Technology Co Ltd
Operating Income
Tianjin Ringpu Bio-Technology Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
|
Operating Income
¥403.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
19%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Operating Income
¥3.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥5.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
1%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
-¥749.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tianjin Ringpu Bio-Technology Co Ltd
Glance View
Tianjin Ringpu Bio-Technology Co., Ltd. has carved a niche for itself as a formidable player in the animal health and nutrition industry. Founded in 1998, the company has steadily expanded its portfolio, offering a diverse range of products designed to enhance the health and productivity of livestock and pets. Ringpu's operations are tightly integrated across research, development, production, and sales of veterinary vaccines, medicines, and feed additives. By leveraging cutting-edge biotechnology, Ringpu devises innovative solutions that meet the rigorous standards of animal health care. Its research facilities are at the forefront of developing vaccines that guard against prevalent livestock and pet diseases, ensuring that its offerings remain both effective and relevant. The company's ability to generate revenue hinges on its extensive distribution network and the strategic partnerships it has fostered within China and globally. Ringpu sells its products through a well-established sales force that connects with farmers, livestock producers, and veterinary clinics, providing not just products but also comprehensive health management solutions. Additionally, the company invests heavily in fostering relationships with academic institutions and research bodies, ensuring a steady pipeline of groundbreaking discoveries and innovations. This approach not only bolsters the company's reputation in the industry but also guarantees a sustained stream of income as more clients turn to Ringpu for reliable and sophisticated animal healthcare solutions.
See Also
What is Tianjin Ringpu Bio-Technology Co Ltd's Operating Income?
Operating Income
403.3m
CNY
Based on the financial report for Sep 30, 2024, Tianjin Ringpu Bio-Technology Co Ltd's Operating Income amounts to 403.3m CNY.
What is Tianjin Ringpu Bio-Technology Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
19%
Over the last year, the Operating Income growth was 3%. The average annual Operating Income growth rates for Tianjin Ringpu Bio-Technology Co Ltd have been -2% over the past three years , 12% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
